Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy

详细信息    查看全文

• 作者：Dean J. Kereiakes ; MD^a ; ^{lindner@thechristhospital.com} ; Stephen G. Ellis ; MD^b ; Takeshi Kimura ; MD^c ; Alexandre Abizaid ; MD ; PhD^d ; Weiying Zhao ; MD ; PhD^e ; Susan Veldhof ; RN^e ; Minh-Thien Vu ; MS^e ; Zhen Zhang ; PhD^e ; Yoshinobu Onuma ; MD ; PhD^f ; Bernard Chevalier ; MD^g ; Patrick W. Serruys ; MD ; PhD^h ; Gregg W. Stone ; MDⁱ ; ^j
• 关键词：bioresorbable vascular scaffolds ; coronary artery disease ; diabetes
• 刊名：JACC: Cardiovascular Interventions
• 出版年：2017
• 出版时间：9 January 2017
• 年：2017
• 卷：10
• 期：1
• 页码：42-49
• 全文大小：585 K
• 卷排序：10

文摘

The study sought to evaluate the efficacy and safety of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) (Abbott Vascular, Abbott Park, Illinois) in patients with diabetes mellitus.BackgroundRandomized, controlled trials have demonstrated comparable clinical outcomes following percutaneous coronary intervention with either Absorb BVS or metallic Xience everolimus-eluting stent. However, these trials lack power required to provide reliable treatment effect estimates in this high-risk population.MethodsIn a pre-specified, powered analysis, patients with diabetes who received ≥1 Absorb were pooled from the ABSORB II, III, and JAPAN randomized trials and from the single arm ABSORB EXTEND registry. The study composite primary endpoint was target lesion failure (TLF) at 1 year following Absorb BVS compared with a performance goal of 12.7%.ResultsAmong 754 diabetic patients included in analysis (27.3% insulin treated), the 1-year TLF rate was 8.3% (upper 1-sided 95% confidence limit: 10.1%; p = 0.0001 vs. performance goal). Scaffold thrombosis (definite or probable) was observed in 2.3% of patients. Multivariable regression identified older age, insulin treatment, and smaller pre-procedure reference vessel diameter as significant independent predictors of 1-year TLF.ConclusionsThe Absorb diabetic substudy suggests efficacy and safety of the Absorb BVS for treatment of patients with diabetes mellitus.